Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Although new medicines can help you lose weight faster and healthier than ever, a new psychology is needed to keep your ...

Eli Lilly (LLY) stock recovers as company executives seize a rare buying opportunity to make a series of insider purchases ...

Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...

CBER Chief Vinay Prasad reclaimed his job less than two weeks after his mysterious exit; MAHA implementor Gray Delany is out ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company recently completed a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...

A Legionnaires' disease outbreak in New York's Central Harlem neighborhood has now sickened 90 people and caused three deaths ...

Artificial intelligence programs can help doctors and nurses predict hours earlier which ER patients will likely require ...